前列腺腺癌脑及肌肉转移初由177Lu-PSMA SPECT/CT显示
本文报告一例68岁转移性去势抵抗性前列腺癌患者,接受多周期177Lu-PSMA治疗后,末次治疗后SPECT/CT提示右侧颞叶脑及肌肉少见转移模式,68Ga-PSMA PET/CT与脑MRI证实上述发现;患者随访3个月至结束仍无症状,提示当其他生物标志物不能定论时治疗后闪烁显像的重要性。
要点
- 68岁转移性去势抵抗性前列腺癌患者接受多周期177Lu-PSMA治疗。
- 末次治疗后SPECT/CT提示右侧颞叶脑及肌肉少见转移模式。
- 68Ga-PSMA PET/CT与脑MRI证实上述发现,患者随访3个月仍无症状。
核心结论
- 本病例强调当其他生物标志物不能定论时,治疗后闪烁显像具有重要性。
研究设计与样本
- 本文为病例报告,报告一例68岁转移性去势抵抗性前列腺癌患者。
主要发现
- 患者接受多周期177Lu-PSMA治疗,末次治疗后SPECT/CT提示疾病进展,表现为右侧颞叶脑及肌肉少见转移模式。
- 68Ga-PSMA PET/CT与脑MRI证实上述发现。
- 患者随访持续3个月,至随访结束仍无症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cerebral and muscular metastases from prostatic adenocarcinoma occur rarely. Patients who develop such metastatic pattern exhibit noticeable symptoms. Herein, we present a 68-year-old man diagnosed with metastatic castrate-resistant prostate cancer. The patient received multiple 177 Lu-PSMA cycles. After the last cycle, a posttreatment SPECT/CT suggested disease progression with uncommon metastatic pattern in the right temporal brain lobe and muscles. 68 Ga-PSMA PET/CT and brain MRI confirmed these findings. Surprisingly, the patient remained asymptomatic up until the conclusion of the follow-up, which lasted for 3 months. This case emphasizes the importance of posttreatment scintigraphic imaging when other biomarkers are inconclusive.
引用
- Al-Ibraheem A, Istatieh F, Abdlkadir AS, et al. Cerebral and Muscular Metastases From Prostate Adenocarcinoma Initially Depicted by 177 Lu-PSMA SPECT/CT. Clin Nucl Med. 2024. PMID: 38271240. doi:10.1097/RLU.0000000000005050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。